Free Trial

Standard BioTools (LAB) Competitors

Standard BioTools logo
$1.25 +0.03 (+2.05%)
As of 10:36 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

LAB vs. TXG, TRNS, EYPT, ALNT, CTKB, AEHR, SENS, QSI, QTRX, and MASS

Should you be buying Standard BioTools stock or one of its competitors? The main competitors of Standard BioTools include 10x Genomics (TXG), Transcat (TRNS), Eyepoint Pharmaceuticals (EYPT), Allient (ALNT), Cytek Biosciences (CTKB), Aehr Test Systems (AEHR), Senseonics (SENS), Quantum-Si (QSI), Quanterix (QTRX), and 908 Devices (MASS). These companies are all part of the "measuring and control equipment" industry.

Standard BioTools vs. Its Competitors

Standard BioTools (NASDAQ:LAB) and 10x Genomics (NASDAQ:TXG) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

Standard BioTools has higher earnings, but lower revenue than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Standard BioTools$174.43M2.71-$138.88M-$0.35-3.56
10x Genomics$610.78M2.49-$182.63M-$1.30-9.51

In the previous week, 10x Genomics had 3 more articles in the media than Standard BioTools. MarketBeat recorded 4 mentions for 10x Genomics and 1 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 1.89 beat 10x Genomics' score of 0.62 indicating that Standard BioTools is being referred to more favorably in the media.

Company Overall Sentiment
Standard BioTools Very Positive
10x Genomics Positive

53.7% of Standard BioTools shares are owned by institutional investors. Comparatively, 84.7% of 10x Genomics shares are owned by institutional investors. 23.2% of Standard BioTools shares are owned by company insiders. Comparatively, 10.0% of 10x Genomics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Standard BioTools has a beta of 1.54, indicating that its share price is 54% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 2.03, indicating that its share price is 103% more volatile than the S&P 500.

Standard BioTools currently has a consensus target price of $2.50, indicating a potential upside of 100.80%. 10x Genomics has a consensus target price of $14.13, indicating a potential upside of 14.29%. Given Standard BioTools' stronger consensus rating and higher possible upside, research analysts clearly believe Standard BioTools is more favorable than 10x Genomics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Standard BioTools
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
10x Genomics
1 Sell rating(s)
5 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.46

10x Genomics has a net margin of -25.14% compared to Standard BioTools' net margin of -78.24%. Standard BioTools' return on equity of -22.44% beat 10x Genomics' return on equity.

Company Net Margins Return on Equity Return on Assets
Standard BioTools-78.24% -22.44% -16.74%
10x Genomics -25.14%-23.22%-18.02%

Summary

Standard BioTools beats 10x Genomics on 10 of the 16 factors compared between the two stocks.

Get Standard BioTools News Delivered to You Automatically

Sign up to receive the latest news and ratings for LAB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LAB vs. The Competition

MetricStandard BioToolsMEDICAL INFO SYS IndustryMedical SectorNASDAQ Exchange
Market Cap$476.67M$1.97B$5.56B$9.28B
Dividend YieldN/AN/A4.23%4.03%
P/E Ratio-3.5934.3928.6419.62
Price / Sales2.7114.86430.8295.68
Price / CashN/A54.7436.0257.93
Price / Book0.988.458.155.59
Net Income-$138.88M-$62.39M$3.24B$257.73M
7 Day Performance-8.46%-1.98%-0.64%-0.23%
1 Month Performance13.18%9.98%4.92%7.98%
1 Year Performance-45.63%3.41%25.99%13.16%

Standard BioTools Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LAB
Standard BioTools
3.798 of 5 stars
$1.25
+2.0%
$2.50
+100.8%
-42.2%$476.67M$174.43M-3.59620Positive News
TXG
10x Genomics
4.5664 of 5 stars
$12.47
-2.6%
$14.13
+13.3%
-29.4%$1.54B$624.66M-9.591,240Gap Up
TRNS
Transcat
2.9137 of 5 stars
$86.45
-0.2%
$112.20
+29.8%
-36.9%$805.71M$278.42M55.421,245
EYPT
Eyepoint Pharmaceuticals
1.593 of 5 stars
$10.17
-1.8%
$25.67
+152.4%
-6.6%$699.81M$56.04M-4.22120
ALNT
Allient
2.2358 of 5 stars
$39.11
+1.3%
$31.00
-20.7%
+44.4%$662.09M$516.06M66.292,525
CTKB
Cytek Biosciences
3.0432 of 5 stars
$3.35
-2.9%
$5.60
+67.2%
-48.7%$424.31M$197.05M-37.22500News Coverage
AEHR
Aehr Test Systems
3.4308 of 5 stars
$13.86
-1.8%
$25.00
+80.4%
-14.5%$412.61M$58.97M-106.6190
SENS
Senseonics
1.9974 of 5 stars
$0.49
-0.8%
$1.70
+244.9%
+11.3%$322.46M$23.68M-3.7990News Coverage
Analyst Forecast
Analyst Revision
Gap Up
QSI
Quantum-Si
1.8135 of 5 stars
$1.73
flat
$3.48
+100.9%
+59.3%$317.45M$3.44M-2.54150Gap Down
QTRX
Quanterix
2.5631 of 5 stars
$6.05
+2.7%
$13.50
+123.1%
-63.6%$302.20M$137.42M-4.65460
MASS
908 Devices
1.1126 of 5 stars
$6.72
-3.2%
$5.33
-20.6%
+17.5%$240.98M$59.63M-12.4460Positive News

Related Companies and Tools


This page (NASDAQ:LAB) was last updated on 7/16/2025 by MarketBeat.com Staff
From Our Partners